Compare ZURA & FBYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZURA | FBYD |
|---|---|---|
| Founded | 2022 | 2021 |
| Country | United States | United States |
| Employees | 40 | 243 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.4M | 811.6M |
| IPO Year | N/A | N/A |
| Metric | ZURA | FBYD |
|---|---|---|
| Price | $4.37 | $17.05 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | ★ 627.8K | 58.9K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $268.88 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.99 | $3.71 |
| 52 Week High | $7.25 | $29.02 |
| Indicator | ZURA | FBYD |
|---|---|---|
| Relative Strength Index (RSI) | 38.08 | 61.25 |
| Support Level | $3.33 | $10.17 |
| Resistance Level | $4.58 | $18.77 |
| Average True Range (ATR) | 0.36 | 2.11 |
| MACD | -0.03 | 0.45 |
| Stochastic Oscillator | 26.33 | 59.27 |
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
Falcons Beyond Global Inc is a visionary entertainment and technology enterprise. The group designs, develops, engineers, delivers, and commercializes immersive physical and digital experiences for brands, developers, and destination operators world-wide, as well as for its own portfolio of entertainment and technology concepts. The Company has five operating segments: Falcon's Creative Group, Destinations Operations, PDP, Falcon's Beyond Brands, and Falcon's Attractions. It earns the majority of the revenue from Falcon's Creative Group segment.